KEY TAKEAWAYS
- The study aimed to investigate the impact of BEV on survival outcomes in patients with PR-ROC in real-world clinical practice.
- The primary endpoint was to determine PFS.
- The study concluded that BEV improved OS in patients with PR-ROC, with manageable toxicity in real-world clinical practice.
Over the past several decades, advancements in anti-cancer drugs have significantly influenced the management of epithelial ovarian cancer (OC), improving patient outcomes. Among these drugs, BEV has emerged as a promising option for advanced or recurrent OC.
Aeran Seol and the team aimed to assess the effectiveness of BEV in patients with platinum-resistant relapsed epithelial ovarian cancer (PR-ROC).
They performed an inclusive analysis by retrospectively dividing patients with PR-ROC into two groups: BEV plus chemotherapy (BEV-CT group) and chemotherapy alone (CT group). The primary endpoint, progression-free survival (PFS), was compared between the two groups to assess whether survival outcomes were improved by adding bevacizumab.
Overall survival (OS) was compared to evaluate the impact of BEV on long-term survival outcomes in this patient population.
About 154 patients were included in the study. 57 in the BEV-CT group and 97 in the CT group. OS was significantly longer in the BEV-CT group compared to the CT group. The use of BEV was identified as a favorable prognostic factor for OS. Subgroup analysis focusing on 2L chemotherapy revealed statistically significant differences in PFS and OS between the two groups.
Additionally, a higher incidence of adverse hematologic events in grades 3 or above was observed in the CT group compared to the BEV-CT group.
The study concluded that in a real-world clinical setting, the introduction of BEV improved OS among patients with PR-ROC, with tolerable toxicity.
The study was sponsored by the National Research Foundation of Korea funded by the Ministry of Science and ICT, and the Cooperative Research Program of Basic Medical Science and Clinical Science of Seoul National University College of Medicine.
Source: https://pubmed.ncbi.nlm.nih.gov/38688599/
Seol A, Kim SI, Yoon HY, et al. (2024). “Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.” In Vivo. 2024 May-Jun;38(3):1338-1350. doi: 10.21873/invivo.13574. PMID: 38688599.
